
News|Articles|August 1, 2005
Dual peroxisome proliferator-activated receptor agonist demonstrates significant lipid benefits
Phase 3 clinical trial results have demonstrated that the dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist muraglitazar achieves significant beneficial lipid effects compared with pioglitazone, and the agent also provides long-term glycemic control in type 2 diabetics. The results were reported during the American Diabetes Association (ADA) 65th Annual Meeting in San Diego, Calif.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
What UnitedHealth Group’s earnings call reveals about managed care trends
3
Could GLP-1s help with cognitive symptoms, pychosis of schizophrenia?
4
Medicaid tech companies pledge $600 million to help states update systems
5























